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High-mobility group box 1 (HMGB1) is a leaderless cytokine, like the IL-1 and FGF family
members, that has primary roles within the nucleus and the cytosol. Within the nucleus, it
serves as another guardian of the genome, protecting it from oxidant injury and promoting
access to transcriptional complexes such as nuclear hormone/nuclear hormone receptors
and p53/p73 complexes. Within the cytosol it promotes autophagy and recruitment of the
myddosome toToll-like receptor (TLR) 9 vesicular compartments. Outside of the cell, it can
either bind to specific receptors itself, or with high affinity to DNA, nucleosomes, IL-1β,
lipopolysaccharide, and lipoteichoic acid to mediate responses in specific physiological or
pathological conditions. Currently identified receptors includeTLR2,TLR4, the receptor for
advanced glycation end products, CD24-Siglec G/10, chemokine CXC receptor 4, and TIM-
3. In terms of its effects or functions within lymphoid cells, HMGB1 is principally secreted
from mature dendritic cells (DCs) to promote T-cell and B-cell reactivity and expansion and
from activated natural killer cells to promote DC maturation during the afferent immune
response. Some studies suggest that its primary role in the setting of chronic inflammation
is to promote immunosuppression. As such, HMGB1 is a central cytokine for all lymphoid
cells playing a role complementary to its better studied role in myeloid cells.
Keywords: lymphocytes, HMGB1,TLR2,TLR4, RAGE, NK cells,T cells, B cells
INTRODUCTION
Damage-associated molecular pattern (DAMPs) molecules, are
endogenous danger signals that elicit inflammation and subse-
quent immune responses once released from dead or stressed cells
following injury or infection (Rubartelli and Lotze, 2007; Sims
et al., 2010; Tang et al., 2012). Although various DAMPs have
been identified, the best characterized is the prototypic nuclear
protein high-mobility group box 1 (HMGB1). HMGB1 is an evo-
lutionarily ancient protein that was first discovered as a chromatin-
associated protein more than three decades ago (Goodwin et al.,
1977). We now know that it displays many other functions depend-
ing on its location and its synergizing partners. Present within
the nuclei of almost all eukaryotic cells, HMGB1 functions as a
DNA chaperone that stabilizes nucleosome formation and pro-
motes access to transcriptional factors that target specific genes
(Müller et al., 2001; Thomas, 2001), although HMGB1 itself
is not sequence specific. Our group demonstrated that cytoso-
lic HMGB1 also promotes autophagy, a conserved programed
survival pathway evoked following environmental and intracel-
lular stress (Tang et al., 2010a, 2012). Apart from its nuclear and
cytosolic roles, HMGB1 possesses a previously unexpected mul-
tifaceted role in immunity when released or secreted into the
extracellular milieu. This occurs in two principal ways: either
(1) passively released from necrotic cells (Scaffidi et al., 2002)
or (2) actively secreted by inflammatory cells, such as mono-
cytes or macrophages (Gardella et al., 2002; Bonaldi et al., 2003;
Tang et al., 2007) and natural killer (NK) cells (Semino et al.,
2005; Gougeon and Bras, 2011). It this way, HMGB1 evokes
innate immune response via its interaction with cell surface
receptors.
Previous studies highlight the importance of HMGB1 at the
core of inflammation-associated events, acting as an irreplaceable
modulator of immune responses and the “universal” biosensor for
nucleic acids (Yanai et al., 2012). In spite of its well-established
divergent functions in myeloid cells which predominantly partic-
ipate in innate immune response, its roles in adaptive immunity
involving T-cells and B-cells is so far not fully understood and
surprisingly, one which needs substantially more study. Here, we
describe the cytokine-like biology of HMGB1 protein, with a focus
on lymphoid cells, including NK cells, T-cells, and B-cells.
LESSONS FROM HMGB1 KNOCKOUTS
High-mobility group box 1 is vital for ex utero growth, as shown
by inborn defects and rapid death (within 24 h following birth)
in hmgb1−/− mice, as early as E15 in inbred species, because
of hypoglycemia. This was initially postulated to be the result
from deficient glucocorticoids receptor function (Calogero et al.,
1999), but we would now attribute this to reduced autophagy, crit-
ically important for survival in the neonatal period (Kuma et al.,
2004). Necrotic HMGB1−/− cells only weakly activate dendritic
cells (DCs) (Rovere-Querini et al., 2004), and HMGB1-deficient
DCs display sharply impaired capacity to trigger inflammation
(Scaffidi et al., 2002). We now know that floxed HMGB1 deleted
in a tissue- or cell type-specific fashion within the pancreas, liver,
small bowel, DCs, and NK cells, is associated with prolonged via-
bility of animals compared with complete knockout of HMGB1
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(unpublished observations) in the whole animal, suggesting that
these are not the target tissues associated with lethality.
HMGB1 AS THE CYTOKINE FOR LYMPHOID CELLS
High-mobility group box 1 was identified as a delayed mediator
of inflammation released from macrophages (Wang et al., 1999),
found in the serum 24–48 h later than secretion IL-1β and tumor
necrosis factor (TNF)-α, the classical early pro-inflammatory
cytokines which are dissipated by 24 h. Afterwards, it was demon-
strated to be liberated from cells undergoing necrosis, followed by
production of TNF-α from monocytes (Scaffidi et al., 2002). Sub-
sequent investigations uncovered an amazingly profligate role in
mediating local or systemic immune responses through its interac-
tion with several receptors. As a cytokine, it transduces signals and
coordinates cellular activities through several pattern-recognition
receptors including the receptor for advanced glycation end prod-
ucts (RAGE), Toll-like receptor (TLR)2, TLR4, TIM-3, chemokine
CXC receptor (CXCR)4, CD24-Siglec G/10 (Park et al., 2004,
2006; Dumitriu et al., 2005; Lotze and Tracey, 2005; Bianchi,
2009; Chen et al., 2009; Tang and Lotze, 2012; Tang et al., 2012;
Yanai et al., 2012), and TLR-9 when combined with DNA (Tian
et al., 2007). Extracellular HMGB1 thus functions as a modulator,
modifying the immunogenic potentials of DNA and potentially
other PAMPs and DAMPs and cytokines. Indeed, given the dif-
ferences in the all thiol form of HMGB1, promoting primarily
chemokine activity and the dithiol form which promotes TNF/IL-
6 production (cytokine activity), it is quite likely that the molecule
secreted by activated cells, endowed with autocrine and paracrine
actions, differs biochemically and functionally from the molecule
released as a consequence of cell and tissue necrosis (Venereau
et al., 2012). Given this difference with the all thiol form pro-
moting release of the chemokine CXCL12, and the dithiol not,
environmental conditions likely dictate the eventual outcome
of HMGB1 interactions with lymphoid cells in the tissues. For
example, well perfused and non-hypoxic environments may pro-
mote different T-cell responses that hypoxic, reducing conditions
(Venereau et al., 2012). TLRs, the best-studied pattern-recognition
receptors (PRRs), are highly conserved proteins initiating immune
responses following recognition of various molecules derived
from pathogens (PAMPs) as well as endogenous danger signals
(DAMPs) sharing similar structures (Medzhitov and Janeway,
1997; Aderem and Ulevitch, 2000; Medzhitov, 2001). The intra-
cellular signaling cascades after recognition principally involve
two specific adaptors, the Toll/IL-1R domain-containing adap-
tor TRIF and myeloid differentiation primary response protein
(MyD88), which is primarily involved in HMGB1-mediated sig-
naling pathway and acts as a component of myddosome with
IRAK2 and IRAK4 assembled in response to primary stimula-
tion (Motshwene et al., 2009; Lin et al., 2010; George et al.,
2011). RAGE is a PRR with a wide variety of ligands including
advanced glycation end products (AGEs) and DAMPs (Sparvero
et al., 2009; Sims et al., 2010). The list of receptors that inter-
act with HMGB1 continues to grow, as does interest in under-
standing the signaling pathways and their cooperative func-
tions in specific cell types. Current insights on these receptors,
based on experimental observations, is that TLRs principally are
involved in the activation of myeloid cells, whereas RAGE is
primarily activated in endothelial and somatic cells (Yanai et al.,
2012).
High-mobility group box 1 signaling has been studied in
many cell types following interaction with individual receptors,
with most studies centering on myeloid cells – the maturation
of conventional DCs, their role in plasmacytoid DCs, activa-
tion of monocytes or macrophages, and the production of pro-
inflammatory cytokines (Lotze and Tracey, 2005; Yang et al., 2007;
Bianchi, 2009; Yanai et al., 2012). Their effects on lymphoid cells,
however, are surprisingly not well characterized. We have extra-
ordinarily limited information about the expression of receptors
RAGE and, TLR2/4 and TIM-3 on both helper and regulatory
T-cells (Wild et al., 2012), RAGE and TLR2/4/9 on B-cells (Tian
et al., 2007; Avalos et al., 2010), and TLR2/4 and TIM-3 on NK
cells (Tang and Lotze, 2012), shown in Figure 1. Beyond that there
is quite little information. In this review, we summarize the critical
roles of HMGB1 in lymphoid cells (Table 1), with a focus on its
extracellular role acting as a cytokine.
Most cytokines function distinctly in synergy or antago-
nism with other cytokines acting collectively. This is also true
for HMGB1. Moreover, HMGB1 shares pleiotropic and redun-
dant characteristics with other cytokines (Lotze and Tracey,
2005), sometimes binding them to enhance immunologic func-
tion, thereby endowing them with a more potent capacity
to elicit biological and immunological responses, consequences
depending on the local microenvironmental factors and pres-
ence of other circumstances. Here, we list out different cellu-
lar responses of lymphoid cells to HMGB1 in different condi-
tions or settings (Table 2) which could act as a reference for
readers to make comparisons or conduct experiments. Also, we
summarize the common consequences in response to HMGB1
(Figure 2).
HMGB1 AND NK CELLS
There is little information about the direct effects of HMGB1
on NK cells, with the exception of elevated secretion of IFN-γ
by macrophage-stimulated NK cells in concert with other pro-
inflammatory cytokines like IL-2 and IL-12 (DeMarco et al.,
2005), work done by our group almost a decade ago. Nevertheless,
whether it occurs depending on the activation of monocytes or in a
direct NK-cell specific manner is still unclear. Further clarification
as to which cell type is responsive to HMGB1 under these specific
circumstance is needed and of significant interest, since little is
known about the interaction between monocytes (macrophages)
and NK cells, both of which are key sentinels and instigators of
immune responses.
Natural killer cells do, however, secrete HMGB1. HMGB1
undergoes abundant, regulated secretion from activated NK
cells into the immunological synapse during NK/iDC (imma-
ture DC) crosstalk, thus inducing maturation of DCs and lim-
iting NK cell-mediated cytotoxicity of the DCs (Semino et al.,
2005). The secretion of HMGB1 is markedly elevated following
engagement of NKp30 (one type of natural cytotoxicity recep-
tor or NCR) expressed on human NK cells, thereby triggering
maturation of autologous DC (Semino et al., 2007). Whether
or not DC can in turn secrete HMGB1 for further activation
of NK cells and promote the quality of the crosstalk remains
Frontiers in Immunology | Inflammation March 2013 | Volume 4 | Article 68 | 2
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FIGURE 1 | Differential expression of DAMP receptors for HMGB1
on lymphoid cells. Surprisingly, given the surfeit of receptors now
shown to be expressed on various cell types, relatively little has been
done to fully characterize the panoply of receptors on lymphoid cells.
Best defined are the expression of RAGE on Ba and T-cells (but not to
our knowledge on NK cells). Similarly TLR2, TLR4, CXCR4, and possible
TIM-3 could play critical roles on subserving cell functions in response
to HMGB1 on immune cells and this needs to be more carefully
studied. Possible and defined roles are shown. “?” represents we
hypothesize that HMGB1 binds to IL receptors, assisting in interleukin
(cytokine) interaction. Also, expression of other HMGB1 receptors are
unknown at present.
Table 1 | Lymphoid cells respond to HMGB1.
NK cells B-cells T-cells
Nuclear Modulation of transcriptional activity of various genes, including steroid hormone receptors, NF-κB, p53/p73 transcriptional complexes,
and some homeobox-containing protein (Erlandsson Harris and Andersson, 2004; Lotze and Tracey, 2005)
Nuclear assistance in assembly of recombination activating gene 1/2(RAG1/2)-DNA complex
for V(D)J recombination of B-cell receptors (BCR) and T-cell receptors (TCR) (Agrawal and
Schatz, 1997; Dai et al., 2005)
Cytosolic Regulation of autophagy (Tang et al., 2010a) (other cell types, not discovered in lymphoid cells yet)
Recruitment of MyD88 to TLR-9 (Ivanov
et al., 2007)
Universal biosensor of nucleic acid (Yanai et al., 2012)
Extracellular Synergy with other cytokines to modulate cell functions via binding cytokine receptors (CXCR4 for example)
Increased IFN-γ secretion in
macrophage-stimulated NK cells
(DeMarco et al., 2005)
Activation and proliferation in the form of
immune complex (HMGB1+DNA) (Tian
et al., 2007; Avalos et al., 2010)
Expansion, activation, and polarization of Th1
cells (Messmer et al., 2004; Dumitriu and
Baruah, 2005; Sundberg et al., 2009)
Spontaneous IL-8 production (McDonnell
et al., 2011)
Infiltration of T-cells expressing lymphotoxin
and tumor progression (He et al., 2012a)
undefined. Specific cell types without HMGB1 expression would
be needed to uncover the critical role of HMGB1 in intracellular
communication.
High-mobility group box 1-mediated NK/DC crosstalk is
important in the setting of HIV infection (Saïdi et al., 2008;
Melki et al., 2010; Gougeon and Bras, 2011). DCHIV (infected
by HIV virus) are resistant to the NK cell-induced editing
process. Interestingly, HMGB1, essential for DC maturation pre-
sumably within secondary lymphoid tissues, also contributes
to viral replication and DC persistence via up-regulation of
apoptosis inhibitors against TRAIL (TNF-related apoptosis-
inducing ligand)-mediated apoptosis.
Given that the cooperative dialog between NK cells and DCs
is pivotal for sustaining innate immunity and initiating the sub-
sequent adaptive immune response, it is worth investigating the
detailed mechanism by which NK/DC crosstalk and its altered
processes link to clinical manifestations of diseases, including
cancer, autoimmune, and infectious diseases.
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FIGURE 2 | HMGB1 stimulates effector function from immune cells.
In many instances, HMGB1’s function has been to subserve cell:cell
interactions between lymphoid and myeloid cells. Its clearest definition
has been with NK/macrophage or NK/DC interactions although
suspected roles in B and T-cell activities are supported. What is unclear is
whether these roles are cell type specific and whether HMGB1 might
act in trans between a myeloid and lymphoid cell. “?” represents the
state of uncertainty if HMGB1 plays a role in the setting of macrophage
and NK cell interaction or HMGB1 is secreted from DCs to affect NK cell
function.
HMGB1 AND T-CELLS
Our knowledge of HMGB1 effector functions to T-cells are prin-
cipally based on observations and inferences from the evaluation
of T-cell subsets with the treatment of HMGB1 co-cultured with
DCs. In the presence of other cytokines, HMGB1 can modify
the fate of the overall immune response, promoting immunity or
tolerance as demonstrated by targeting effector T-cells and regula-
tory T-cells (Tregs) reciprocally in response to individual stimuli.
Differences that may have been found in terms of immunity or
tolerance when comparing various observations might be, at least
in part, due to differences in the experimental systems utilized
(dosage, duration, and the presence of other factors) and the phar-
macological inhibitors utilized to block these complex biological
systems in vitro and in vivo. We know little about the effects of
HMGB1 on naïve and memory T-cells as regards alteration in
phenotype or cytokine proficiency among the defined T-cell sub-
sets. In addition, the ability of HMGB1 to either recruit T-cells
to sites of tissue damage or injury, thus allowing effector T-cell
function, or to induce Treg infiltration and expansion is largely
unknown.
DIRECT EFFECTS ON T-CELLS
Acting as a pro-inflammatory cytokine, HMGB1, is not only
released by stressed or necrotic tissues but also translo-
cated and secreted by human DC following PAMP [endo-
toxin/lipopolysaccharide (LPS)] stimulation. It plays a critical role
in promoting expansion, survival, and helper T (Th) 1 polariza-
tion of CD4+ T-cells (Dumitriu and Baruah, 2005; Jube et al.,
2012). Similarly, HMGB1, is also a proliferative signal for both
human CD4+ and CD8+ T-cells in response to suboptimal anti-
CD3 mAb stimulation (Sundberg et al., 2009). The expression
level of CTLA4 and Foxp3 in Treg cells as well as IL-10 secretion
are significantly diminished following HMGB1 treatment. This is
restored by administration of an anti-TLR4 antibody (Zhu et al.,
2011). Altogether, HMGB1 is seemingly necessary for enhancing
immunity through activation of effector T-cells and suppression
of Treg’s. In contrast, HMGB1 can also promote migration and
survival of Treg, whereas it suppresses IFNγ release of conven-
tional T-cells and inhibits their proliferation via TLR4, indicating
that the TCR/co-stimulatory signal is abrogated by HMGB1. Fur-
thermore, HMGB1 elicits increased suppressive capacity of Treg
when co-cultured with effector T-cells in a RAGE-dependent fash-
ion. Additionally, several reports provide evidence suggesting that
HMGB1 may contribute to Th17 cells proliferation and activa-
tion in the context of autoimmune disease, including rheumatoid
arthritis, myocarditis, as well as acute allograft rejection (Duan
et al., 2011; Su et al., 2011; He et al., 2012b; Shi et al., 2012).
When we examine immune responses in vivo, the findings are
totally different. HMGB1 is essential for infiltration and activation
of T-cells expressing lymphotoxin α1β2(LT) in mice with prostate
cancer, therefore recruiting macrophages to promote tumor malig-
nant progression (He et al., 2012a). This work further confirms
the notion that HMGB1 can prompt progression of many types
of cancers (Tang et al., 2010b). Surprisingly, neither T effectors
nor Tregs are detected differentially between normal and can-
cerous tissues. The source of extracellular HMGB1 needs to be
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further characterized, whether arising from stressed tumor cells
or recruited inflammatory cells, including NK cells or DCs, or all.
HMGB1 markedly limits the proliferation of murine (rat) T-cells
and induces Th2 polarization following burn injury, consistent
with decreased expression of IL-2 and IL-2Rα (Zhang et al., 2008).
DC-MEDIATED INDIRECT EFFECTS ON T-CELLS
High-mobility group box 1 is an inducer of DC maturation
(Messmer et al., 2004; Rovere-Querini et al., 2004; Semino et al.,
2005, 2007). Mature and activated DC will further drive Th1
polarization, as evidenced by secretion of IL-2 and IFN-γ (Mess-
mer et al., 2004). It is worth noting that one of the promising
mechanisms underlying the chemo- or radio-therapy-based anti-
tumor responses is due to the functional binding between HMGB1
released by dying cells and one of its receptors, TLR4 expressed
on DC, which allows for antigen presentation and subsequent
cytotoxic CD8+ T-cell (CTL) effector function (Apetoh et al.,
2007).
On the other hand, IL-10 producing CD11Clow CD45RBhigh
mouse DCs also display a mature phenotype and secrete IL-10 fol-
lowing HMGB1 stimulation in a dose-dependent manner, thereby
potentially diminishing T-cell responses with down-regulation of
IL-2 and IL-2Rα and driving Th2 polarization, just the opposite in
the case of CD11Chigh CD45RBlow DCs. This finding is in concor-
dance with the potential of HMGB1 to polarize Th2 cells in rats
following thermal injury (Zhang et al., 2008).
HMGB1 AND B-CELLS
Compared with T-cells, the role of HMGB1 in B-cells has not been
fully delineated. Some studies have supported a role for HMGB1
in B-cell activation. In the form of immune complexes (ICs),
HMGB1 promotes proliferation of autoreactive B-cells in response
to endogenous TLR-9 ligands (e.g., DNA) (Tian et al., 2007; Ava-
los et al., 2010). This suggests are markedly immune-regulatory
function in the pathogenesis of autoimmune diseases. TLR-9 is
responsive to immune complex in intracellular endosomes, while
the internalization of DNA may be mediated by RAGE which
bound with HMGB1 (Tian et al., 2007) or by specific IgG and
B-cell receptor interaction, followed by BCR engagement (Avalos
et al., 2010). However, given that B-cell proliferation and Ig gene
recombination share the same pathway but contrary states of mol-
ecules involved (e.g., FOXO degradation or dephosphorylation)
and autoreactive antigen, the capacity of antibody production
could be further investigated in terms of individual receptors of
IC interaction, thus providing a comprehensive role for HMGB1
in B-cell activation. Furthermore, in the context of inflamma-
tory bowel disease (IBD), enhanced serum levels of HMGB1 is
accompanied by spontaneous IL-8 production by B-cells via inter-
action with TLR2 and CD36 (McDonnell et al., 2011). On the
other hand, plasma cells release HMGB1 into the extracellular
milieu following LPS-stimulated maturation (Vettermann et al.,
2011), demonstrating its pro-inflammatory effects in promoting
autoimmune disease and chronic inflammation.
CONCLUDING REMARKS
High-mobility group box 1, like other cytokines, is able to function
as an agonist, an antagonist, to synergize with other factors and to
have multiple pleiotropic functions on multiple cell types, includ-
ing lymphoid cells. Unlike typical cytokines however, it interacts
with a panoply of receptors, many of which are notably promis-
cuous with functions quite disparate from each other, depending
upon the local microenvironment, location,and coordination with
individual stimuli. In addition, unlike cytokines which interact
with picogram or nanogram quantities to promote full recep-
tor activation, HMGB1 requires, in many instances, microgram
quantities in order to elicit a meaningful response in vitro. Increas-
ing advances in understanding the role of HMGB1 in immunity
have extended the knowledge and led to widespread acceptance
of the notion that HMGB1 acts as a centrally important, potent,
ubiquitous cytokine which exerts effect on both myeloid and
lymphoid cells. It thus plays a multifaceted modulatory role in
both innate and adaptive immune responses. Although there is
much information about the diverse, sometimes even opposite
effects of HMGB1 on various kinds of immune cells in culture,
it is of great importance to understand the precise mechanism
by which HMGB1 functions in vivo, in particular during altered
pathology or physiology. In a complicated balance of guiding and
choreographing disparate biologies, HMGB1, interspersed with
DAMPs and PAMPs, develops the plot line and provides impe-
tus to the emergent immune response. Improved understanding
of when, where, which cell types produce/respond to HMGB1
and what levels at intimate cell:cell contact or released into tis-
sues or systemically would provide a basis for suitable therapeutic
implementation or interventions in the clinic.
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